Literature DB >> 6628505

Cimetidine disposition in patients with Laennec's cirrhosis during multiple dosing therapy.

J P Cello, S Oie.   

Abstract

The disposition of cimetidine after oral and intravenous administration during multiple dosing was studied in 11 patients with Laennec's cirrhosis. The average metabolic clearance of cimetidine in these patients was 15 l/h, similar to values reported for normal subjects. However, in 4 subjects with plasma prothrombin times above normal, the metabolic clearance was significantly decreased and ranged between 4.3 and 13.0 l/h. The renal clearance of cimetidine was proportional to the creatinine clearance in all subjects, regardless of the severity of the liver disease. The clearance of cimetidine in patients with Laennec's cirrhosis, therefore, appears to be predictable from creatinine clearance and prothrombin time.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6628505     DOI: 10.1007/bf00543795

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  28 in total

1.  [Cholestatic hepatosis under Cimetidine].

Authors:  H Züchner
Journal:  Dtsch Med Wochenschr       Date:  1977-12-02       Impact factor: 0.628

2.  Oral absorption of cimetidine and its clearance in patients with renal failure.

Authors:  R Larsson; G Bodemar; B Norlander
Journal:  Eur J Clin Pharmacol       Date:  1979-04-17       Impact factor: 2.953

3.  Bioavailability and pharmacokinetics of cimetidine.

Authors:  A Grahnén; C von Bahr; B Lindström; A Rosén
Journal:  Eur J Clin Pharmacol       Date:  1979-11       Impact factor: 2.953

4.  Cimetidine toxic reactions masquerading as delirium tremens.

Authors:  W W Weddington; A E Muelling; H H Moosa; C P Kimball; R R Rowlett
Journal:  JAMA       Date:  1981-03-13       Impact factor: 56.272

5.  [Plasma concentrations of cimetidine in cirrhotic and non-cirrhotic patients with upper digestive tract hemorrhage (author's transl)].

Authors:  T Dupont; M Beaugrand; J M Brunet; M Azouz-Abdallah; D Baylocq; G Champault; J P Ferrier
Journal:  Gastroenterol Clin Biol       Date:  1981-02

6.  Renal failure with cimetidine.

Authors:  J L Teruel; P Garcia-Cosmes; R Marcen; J Ortuno
Journal:  Ann Intern Med       Date:  1981-04       Impact factor: 25.391

7.  Acute interstitial nephritis and acute renal failure associated with cimetidine therapy.

Authors:  A V Richman; J L Narayan; J S Hirschfield
Journal:  Am J Med       Date:  1981-06       Impact factor: 4.965

8.  Effects of renal failure on blood levels of cimetidine.

Authors:  K W Ma; D C Brown; D S Masler; S E Silvis
Journal:  Gastroenterology       Date:  1978-02       Impact factor: 22.682

9.  Influence of cimetidine on the pharmacokinetics of desmethyldiazepam and oxazepam.

Authors:  U Klotz; I Reimann
Journal:  Eur J Clin Pharmacol       Date:  1980-11       Impact factor: 2.953

10.  Cimetidine clearance and bioavailability in hepatic cirrhosis.

Authors:  J Sonne; H E Poulsen; M Døssing; N E Larsen; P B Andreasen
Journal:  Clin Pharmacol Ther       Date:  1981-02       Impact factor: 6.875

View more
  7 in total

Review 1.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 3.  Guide to drug dosage in hepatic disease.

Authors:  N M Bass; R L Williams
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

Review 4.  Effect of hepatic insufficiency on pharmacokinetics and drug dosing.

Authors:  R K Verbeeck; Y Horsmans
Journal:  Pharm World Sci       Date:  1998-10

Review 5.  Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.

Authors:  Roger K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  2008-09-02       Impact factor: 2.953

6.  Comparative pharmacokinetics and cardiovascular effects of tiapamil in healthy volunteers and patients with hepatic cirrhosis.

Authors:  P H Hinderling; M Eckert; S Gasic; H G Eichler; R Pötzi; P Heizmann
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Binding and disposition of sulfisoxazole in alcoholic cirrhosis.

Authors:  J P Cello; S Oie
Journal:  J Pharmacokinet Biopharm       Date:  1985-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.